Home/Filings/4/0001451612-25-000014
4//SEC Filing

Booth Bruce 4

Accession 0001451612-25-000014

CIK 0001815442other

Filed

Dec 11, 7:00 PM ET

Accepted

Dec 12, 6:37 PM ET

Size

27.8 KB

Accession

0001451612-25-000014

Insider Transaction Report

Form 4
Period: 2025-12-10
Booth Bruce
Director
Transactions
  • Sale

    Common Stock

    2025-12-10$88.64/sh31,459$2,788,5264,141,757 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-12-10$89.25/sh17,825$1,590,8814,123,932 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-12-10$90.14/sh10,545$950,5264,113,387 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-12-10$92.41/sh47,349$4,375,5214,066,038 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-12-10$93.20/sh85,862$8,002,3383,980,176 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-12-10$88.64/sh5,979$529,979717,267 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-12-10$89.25/sh3,391$302,647713,876 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-12-10$90.14/sh2,001$180,370711,875 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-12-10$92.41/sh9,060$837,235702,815 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-12-10$93.20/sh16,338$1,522,702686,477 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-12-11$91.23/sh5,125$467,5543,975,051 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-12-11$91.23/sh976$89,040685,501 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-12-12$91.04/sh570$51,8933,974,481 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-12-12$91.04/sh108$9,832685,393 total(indirect: See footnote)
Footnotes (9)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (1), (3), (4), (5), (6), (8) and (9).
  • [F2]These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.00 to $89.71 inclusive.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.55 inclusive.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.9969 inclusive.
  • [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.6935 inclusive.
  • [F7]The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
  • [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.54 inclusive.
  • [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.33 inclusive.

Issuer

Kymera Therapeutics, Inc.

CIK 0001815442

Entity typeother

Related Parties

1
  • filerCIK 0001451612

Filing Metadata

Form type
4
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 6:37 PM ET
Size
27.8 KB